In continuing efforts to advance the field of Protein Modification Technologies, Advanced Proteome Therapeutics (APT) has filed what it believes is a landmark patent application this month on inventions related to its Swift Linkage Multivalent Technology (SMLT). This Patent, along with previous discoveries, represents a milestone in the company's development and is a significant step toward commercialization.
Protein therapeutics is the fastest growing segment of the pharmaceutical market, with sales projected to be in the 75 billion dollar range by 2013. The company feels it is well positioned, by virtue of discoveries related to SLMT, to capitalize on this growing market with its own internal projects as well as those of potential partners.
This advanced technology is currently being applied internally to protein targets aimed at treating cancer, Crohn's disease, arthritis, obesity, atherothrombosis and plaque rupture. In conjunction with the company's internal progress, this patent filing allows the company to foster relationships with potential partners, and/or customers that desire to utilize APT technology to further the development of their own programmes.
The company believes that the technology expands commercial opportunities for APT in certain subfields of protein therapeutics that have been especially challenging, providing APT with a competitive edge, and further validating its corporate strategy.
Invented by APT to expand the repertoire of entities that can be rapidly linked to protein sites to generate products for development, the technology enables the rapid attachment of a desired entity to a modified site on a protein surface site-specifically, and to the fullest extent.
APT is a pioneer and leader in the development of Protein Modification Technology which is directed toward altering proteins to improve their therapeutic and industrial potential.